Weekly semaglutide plus fast-acting Lyumjev insulin to ease mealtime care for adults with type 1 diabetes
Alleviating carbohydrate counting in adults with type 1 diabetes with weekly Semaglutide injections added to an automated insulin delivery with Lyumjev
This project tests whether adding weekly semaglutide injections to an automated insulin delivery system that uses fast-acting Lyumjev insulin can make mealtime blood sugar control easier for adults with type 1 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mcgill University Health Ctr Res Inst NIH-funded |
| Lab location | 1 site (Montreal, Canada) |
| Project ID | NIH-11160565 on NIH RePORTER |
What this research studies
You would receive weekly injections of the GLP-1 drug semaglutide or not, while using an automated insulin delivery (AID) system that delivers Lyumjev, a very fast-acting insulin lispro. The study uses a 2×2 design to compare different combinations and measures post-meal glucose levels, time spent in target glucose range, and the burden of carbohydrate counting. Researchers will track glucose with continuous glucose monitoring and monitor weight, appetite, and any side effects. Visits and follow-ups take place at the McGill University Health Centre in Montreal over the study period.
Who could benefit from this research
Good fit: Adults aged 21 and older with type 1 diabetes who use or are willing to use an automated insulin delivery system or insulin pump are the most suitable candidates.
Not a fit: People who are pregnant, under 21, have contraindications to GLP-1 receptor agonists (for example a history of medullary thyroid carcinoma), severe gastroparesis, or who are unwilling to use an AID system may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this approach could reduce the need for precise carbohydrate counting at meals, improve post-meal glucose control, and reduce appetite or body weight for some patients.
How similar studies have performed: GLP-1 receptor agonists have improved glucose control without increasing hypoglycemia in type 2 diabetes, and early studies in type 1 diabetes have shown promising but limited results.
Where this research is happening
Montreal, Canada
- Mcgill University Health Ctr Res Inst — Montreal, Canada (Active)
Researchers
- Principal investigator: Tsoukas, Michael — Mcgill University Health Ctr Res Inst
- Study coordinator: Tsoukas, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.